Women's Wellness: Vaginal atrophy after breast cancer

Breast cancer and its treatments can cause many changes in your body. In addition to breast-related changes, you might also experience menstrual changes, hair loss or skin changes. In some cases, these changes can cause sexual challenges. Vaginal atrophy, a thinning, drying and sometimes irritation of the lining of the vaginal walls, can be one [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news

Related Links:

CONCLUSIONS: Severe CIA occurred in all 68 patients who received FEC and taxane chemotherapy. The present findings provide the first data demonstrating that age was not associated with the degree or incidence of hair loss, but age affected the recovery from CIA. These results contribute more accurate information provision and insights regarding the proper treatment of CIA. PMID: 32944881 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
Drug can be used for alopecia treatment in breast cancer survivors
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news
(George Washington University) Researchers at the George Washington University have found that the hair loss drug spironolactone is not associated with increased risk of female breast cancer recurrence and may be safe to treat female pattern hair loss in breast cancer survivors. Their findings are published in the Journal of the American Academy of Dermatology.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
This genetic association study explores whether an association exists between genetic factors and the development of persistent chemotherapy-induced alopecia in women with breast cancer who are treated with docetaxel.
Source: JAMA Dermatology - Category: Dermatology Source Type: research
CONCLUSIONS: DLYE5953A administered at 2.4 mg/kg has acceptable safety. Preliminary evidence of anti-tumor activity in HER2-negative MBC and NSCLC patients supports further investigation of LY6E as a therapeutic target. PMID: 32694157 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conclusions: The quality of life in women with breast cancer and under chemotherapy was mainly affected by the side effects of the therapy; the most relevant signs and symptoms identified were hair loss, insomnia, and fatigue besides breast symptoms, lower physical functionality, and decreased sensation of sexual pleasure. We recommend intervention strategies aimed at improving the quality of life and the physical and emotional care of these patients. PMID: 32673462 [PubMed - in process]
Source: Biomedica : Revista del Instituto Nacional de Salud - Category: International Medicine & Public Health Tags: Biomedica Source Type: research
Purpose: Permanent chemotherapy-induced alopecia (pCIA) is an increasingly recognised complication of taxane-based chemotherapy that may be associated with significant psychological morbidity [1]. The prevalence of pCIA following docetaxel is poorly understood and there are no published data on paclitaxel chemotherapy. Here we analyse prevalence and patterns of pCIA in patients who received docetaxel or paclitaxel across two UK tertiary cancer centres.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Condition:   Alopecia Intervention:   Procedure: Platelet Rich Plasma system Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
ConclusionsSleep disturbances have lately emerged as the most severe problem in women with OC or BC receiving anticancer therapy. Concerns about family and partner were ranked second in the current study and first in previous investigations.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Alopecia | Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Men | Skin | Women